Nail pigmentation induced by chemotherapy: an observational study of patients with early-stage breast cancer

Kuikui Jiang, Si‐Mei Shi, Qiulian Lin, Peng Sun, Luan Zhang, Zhongyu Yuan, Ruoxi Hong, Yanxia Shi, Xia Liu, Jingmin Zhang, Jiajia Huang, Xiwen Bi, Wen Xia, Qianyi Lu, Qiufan Zheng, Shusen Wang, Fei XuHolistic 2022 · DOI

TL;DR

This prospective study reveals that nearly 90% of early-stage breast cancer patients undergoing standard chemotherapy develop nail pigmentation, with nearly half experiencing severe cases. By introducing a novel standardized scoring system, researchers found that this toxicity onsets rapidly (median 37 days) and recovers slowly, highlighting a significant but often overlooked impact on patient quality of life.

What Problem Does This Paper Address?

While life-saving, chemotherapy regimens involving anthracyclines and taxanes are notorious for a range of side effects. Among these, nail toxicity—specifically melanonychia (pigmentation of the nail plate)—is frequently dismissed by clinicians as a minor "cosmetic" issue. However, for patients, these changes can be emotionally distressing, limit manual activities, and serve as a constant visible reminder of their illness.

The primary challenge is that there is currently no National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) standard for grading nail pigmentation. Most existing data are retrospective or lump nail changes into broad "cutaneous toxicity" categories. This paper seeks to fill that gap by providing a prospective, detailed look at the onset, severity, and recovery patterns of nail changes using a standardized assessment tool.

Methods

The researchers conducted a prospective observational study of 90 early-stage breast cancer patients at the Sun Yat-sen University Cancer Center.

The study’s most significant methodological contribution is the Comprehensive Scoring System for nail pigmentation, which evaluates two dimensions:

  1. Area Score (0–3): Based on the percentage of the nail plate affected (from no change to >2/3 area).
  2. Color Score (0–3): Based on a color card ranging from light gray to black.

A total score of 5 or 6 was classified as "severe." To ensure accuracy, two independent medical staff performed the scoring, and the team used Hematoxylin and Eosin (H&E) staining on nail clippings to biologically confirm the presence of melanin granules.

Datasets

The study utilized a primary clinical dataset of 90 newly diagnosed early-stage breast cancer patients.

  • Demographics: All female, median age of 48.
  • Regimens: Primarily EC/AC (epirubicin/doxorubicin + cyclophosphamide) followed by taxanes (88.9% of the cohort).
  • Follow-up: Median follow-up of 10.2 months, with monthly assessments.

Key Insights and Ideas

  • High Prevalence: The 90% incidence rate found here is significantly higher than in many previous studies (which often cited figures around 54%). The authors attribute this to the sequential use of three different drugs (anthracyclines, cyclophosphamide, and taxanes), all of which can trigger melanocyte activation.
  • The "Severe" Burden: Nearly half (48.9%) of patients reached the "severe" threshold. These patients didn't just have darker nails; they had them for longer. Severe pigmentation lasted a median of 230 days, compared to 198 days for mild cases.
  • Biological Confirmation: Through H&E staining, the researchers confirmed that the pigmentation is caused by an actual increase in melanin granules within the nail plate, rather than simple chemical staining or subungual hemorrhage.
  • Rapid Onset, Glacial Recovery: Pigmentation appears quickly—often within the first two cycles of chemotherapy (median 37 days)—but takes a median of 118 days to show remission after treatment ends.

Key Results

  • Nail Pigmentation: 90.0% (n=81)
  • Onycholysis (nail lifting): 43.3% (n=39)
  • Beau’s Lines (transverse grooves): 21.1% (n=19)
  • Median Onset of Pigmentation: 37 days.
  • Median Duration of Pigmentation: 214 days.
  • Remission Rate: At the latest follow-up, 67.9% of patients had achieved remission of their pigmentation.

Limitations and Future Work

The authors acknowledge a few key limitations:

  • Correlation Challenges: Due to the sample size and the fact that most patients received similar multi-drug "cocktails," the study could not statistically isolate which specific drug or patient characteristic (like skin phototype) was the strongest predictor of onset.
  • Subjectivity: While the scoring system is a step forward, it still relies on visual assessment by clinicians.

Future Directions: The results of this observational study are currently being used as a baseline for intervention trials. The researchers are specifically looking into cryotherapy (using frozen gloves and socks during infusion) to see if localized vasoconstriction can reduce the delivery of chemotherapy drugs to the nail bed and prevent these toxicities from occurring in the first place.

Summary updated

Abstract

Abstract Purpose Chemotherapy-induced nail pigmentation is a common adverse effect, but prospective studies focussing on its onset, recovery, and severity are few. We aim to evaluate the pattern of chemotherapy-induced nail pigmentation in early-stage breast cancer patients by calculating the comprehensive score based on hyperpigmentation area and color depth of the nail plate. Methods This prospective, observational study was conducted between February 2019 and December 2019. Early-stage breast cancer patients scheduled to receive anthracyclines combined with cyclophosphamide or taxane-containing regimens were enrolled. The clinicopathologic characteristics and treatment protocols were collected. The onset, patterns, and duration of nail changes were photographed and recorded regularly. Results A total of 90 patients were enrolled. The most common nail change was nail pigmentation ( n = 81, 90.0%), followed by onycholysis ( n = 39, 43.3%), Beau’s lines ( n = 19, 21.1%), Mees’ lines ( n = 16, 17.8%), Muehrcke’s lines ( n = 7, 7.8%), and hemorrhage ( n = 1, 1.1%). Forty-four (48.9%) patients developed severe nail pigmentation. The median onset time of nail pigmentation was 37 days after the initiation of chemotherapy. At the latest follow-up, 55(67.9%) patients achieved remission of melanonychia with the median recovery time of 118 days. The median duration of nail pigmentation was 214 days. Conclusion Our study revealed the specific pattern of chemotherapy-induced nail pigmentation, which onsets early and recovers slowly with a high incidence of severe nail pigmentation, in early-stage breast cancer patients. The results provide reference for further intervention studies. Trial Registration ClinicalTrials.gov Identifier: NCT04215744 . Registered 30 December 2019—Retrospectively registered.
BibTeX
@inproceedings{jiang2022nail,
  author = {Kuikui Jiang and Si‐Mei Shi and Qiulian Lin and Peng Sun and Luan Zhang and Zhongyu Yuan and Ruoxi Hong and Yanxia Shi and Xia Liu and Jingmin Zhang and Jiajia Huang and Xiwen Bi and Wen Xia and Qianyi Lu and Qiufan Zheng and Shusen Wang and Fei Xu},
  title = {{Nail pigmentation induced by chemotherapy: an observational study of patients with early-stage breast cancer}},
  booktitle = {Holistic},
  year = {2022},
  doi = {10.1007/s44178-022-00008-7},
}
Figure